类风湿性关节炎患者服用甲氨蝶呤、磺胺氮嗪或羟氯喹后抑郁和焦虑状态有何不同?

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL
Mansour Babaei, Mehdi Dorparvar, Behnaz Yousef Ghahari, Behzad Heidari, Hemmat Gholinia, Sussan Moudi
{"title":"类风湿性关节炎患者服用甲氨蝶呤、磺胺氮嗪或羟氯喹后抑郁和焦虑状态有何不同?","authors":"Mansour Babaei, Mehdi Dorparvar, Behnaz Yousef Ghahari, Behzad Heidari, Hemmat Gholinia, Sussan Moudi","doi":"10.15275/rusomj.2023.0305","DOIUrl":null,"url":null,"abstract":"Background — Depression and anxiety are among the most common clinical manifestations in patients with rheumatoid arthritis (RA). Sulfasalazine and hydroxychloroquine are important medications used to treat these patients. Objective — The goal of this study was to compare the occurrence of depression and anxiety in RA patients taking sulfasalazine or hydroxychloroquine for at least six months. Methods — This study included 300 patients with RA referred to inpatient or outpatient departments of a public hospital in northern Iran who were treated with two combination regimens of methotrexate and sulfasalazine or methotrexate and hydroxychloroquine. Participants were assessed on the standard Hospital Anxiety and Depression Scale (HADS) for symptoms of depression and anxiety. Results — The mean HADS depression subscale score was 6.77±3.98 in the hydroxychloroquine group and 3.50±3.53 in the sulfasalazine group (p<0.001). The mean HADS anxiety subscale score was 7.66±4.43 in the hydroxychloroquine group and 5.34±4.35 in the sulfasalazine group (p<0.001). Multiple linear regression analysis revealed a significant difference in the incidence of depression and anxiety between the two treatment groups. Conclusion — A higher prevalence of depression and anxiety was observed in RA patients treated with methotrexate and hydroxychloroquine versus those treated with methotrexate with sulfasalazine.","PeriodicalId":21426,"journal":{"name":"Russian Open Medical Journal","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How Different Is The Status Of Depression And Anxiety In Patients With Rheumatoid Arthritis Receiving Methotrexate With Sulfasalazine Or Hydroxychloroquine?\",\"authors\":\"Mansour Babaei, Mehdi Dorparvar, Behnaz Yousef Ghahari, Behzad Heidari, Hemmat Gholinia, Sussan Moudi\",\"doi\":\"10.15275/rusomj.2023.0305\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background — Depression and anxiety are among the most common clinical manifestations in patients with rheumatoid arthritis (RA). Sulfasalazine and hydroxychloroquine are important medications used to treat these patients. Objective — The goal of this study was to compare the occurrence of depression and anxiety in RA patients taking sulfasalazine or hydroxychloroquine for at least six months. Methods — This study included 300 patients with RA referred to inpatient or outpatient departments of a public hospital in northern Iran who were treated with two combination regimens of methotrexate and sulfasalazine or methotrexate and hydroxychloroquine. Participants were assessed on the standard Hospital Anxiety and Depression Scale (HADS) for symptoms of depression and anxiety. Results — The mean HADS depression subscale score was 6.77±3.98 in the hydroxychloroquine group and 3.50±3.53 in the sulfasalazine group (p<0.001). The mean HADS anxiety subscale score was 7.66±4.43 in the hydroxychloroquine group and 5.34±4.35 in the sulfasalazine group (p<0.001). Multiple linear regression analysis revealed a significant difference in the incidence of depression and anxiety between the two treatment groups. Conclusion — A higher prevalence of depression and anxiety was observed in RA patients treated with methotrexate and hydroxychloroquine versus those treated with methotrexate with sulfasalazine.\",\"PeriodicalId\":21426,\"journal\":{\"name\":\"Russian Open Medical Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Russian Open Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15275/rusomj.2023.0305\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Open Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15275/rusomj.2023.0305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景-抑郁和焦虑是类风湿性关节炎(RA)患者最常见的临床表现。柳氮磺胺吡啶和羟氯喹是治疗这些患者的重要药物。目的:本研究的目的是比较服用磺胺氮嗪或羟氯喹至少6个月的RA患者抑郁和焦虑的发生率。方法:本研究纳入伊朗北部一家公立医院住院或门诊的300例类风湿性关节炎患者,他们接受甲氨蝶呤和磺胺氮嗪或甲氨蝶呤和羟氯喹两种联合治疗方案。根据标准医院焦虑和抑郁量表(HADS)对参与者进行抑郁和焦虑症状的评估。结果-羟氯喹组HADS抑郁亚量表平均得分为6.77±3.98,柳氮磺胺吡啶组平均得分为3.50±3.53 (p < 0.001)。羟氯喹组HADS焦虑亚量表平均得分为7.66±4.43分,磺胺氮嗪组平均得分为5.34±4.35分(p < 0.001)。多元线性回归分析显示,两组患者抑郁、焦虑发生率差异有统计学意义。结论:与甲氨蝶呤联合羟氯喹治疗的RA患者相比,甲氨蝶呤联合磺胺嘧啶治疗的RA患者抑郁和焦虑的发生率更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
How Different Is The Status Of Depression And Anxiety In Patients With Rheumatoid Arthritis Receiving Methotrexate With Sulfasalazine Or Hydroxychloroquine?
Background — Depression and anxiety are among the most common clinical manifestations in patients with rheumatoid arthritis (RA). Sulfasalazine and hydroxychloroquine are important medications used to treat these patients. Objective — The goal of this study was to compare the occurrence of depression and anxiety in RA patients taking sulfasalazine or hydroxychloroquine for at least six months. Methods — This study included 300 patients with RA referred to inpatient or outpatient departments of a public hospital in northern Iran who were treated with two combination regimens of methotrexate and sulfasalazine or methotrexate and hydroxychloroquine. Participants were assessed on the standard Hospital Anxiety and Depression Scale (HADS) for symptoms of depression and anxiety. Results — The mean HADS depression subscale score was 6.77±3.98 in the hydroxychloroquine group and 3.50±3.53 in the sulfasalazine group (p<0.001). The mean HADS anxiety subscale score was 7.66±4.43 in the hydroxychloroquine group and 5.34±4.35 in the sulfasalazine group (p<0.001). Multiple linear regression analysis revealed a significant difference in the incidence of depression and anxiety between the two treatment groups. Conclusion — A higher prevalence of depression and anxiety was observed in RA patients treated with methotrexate and hydroxychloroquine versus those treated with methotrexate with sulfasalazine.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Russian Open Medical Journal
Russian Open Medical Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
0.90
自引率
0.00%
发文量
39
期刊介绍: Russian Open Medical Journal (RusOMJ) (ISSN 2304-3415) is an international peer reviewed open access e-journal. The website is updated quarterly with the RusOMJ’s latest original research, clinical studies, case reports, reviews, news, and comment articles. This Journal devoted to all field of medicine. All the RusOMJ’s articles are published in full on www.romj.org with open access and no limits on word counts. Our mission is to lead the debate on health and to engage, inform, and stimulate doctors, researchers, and other health professionals in ways that will improve outcomes for patients. The RusOMJ team is based mainly in Saratov (Russia), although we also have editors elsewhere in Russian and in other countries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信